Bioniche Life Sciences Obtains Support from Canadian Govt for 2nd Generation E.Coli Vaccine

Bioniche Life Sciences Inc. (TSX:BNC, ASX:BNC) announced that it has been given up to $500,000 contribution from the National Research Council of Canada Industrial Research Assistance Program to help fund its R&D of a second generation E.coli O157 cattle vaccine.

As quoted in the press release:

We are pleased to receive this funding from IRAP,” said Mr. Rick Culbert, President, Bioniche One Health. “We have been working with Dr. Brett Finlay at the University of British Columbia on the development of a second generation E. coli O157 cattle vaccine, which is expected to be safer to make, more readily produced with higher yields than the first generation vaccine, and may have the potential to cross-protect against other E. coli serotypes.

Click here to read the full Bioniche Life Sciences Inc. (TSX:BNC, ASX:BNC) press release.